Insiders · AKRO

Patrick Lamy

Senior VP, Commercial Strategy at Akero Therapeutics, Inc. (AKRO) since January 2023

Patrick Lamy has filed 18 insider reports with the SEC since January 2023, as senior VP and commercial Strategy at Akero Therapeutics, Inc. (AKRO). Patrick Lamy made no open-market purchases or sales in the last 12 months. The latest filing, on December 9, 2025, reports sale back to the company at Akero Therapeutics, Inc. (AKRO).

Filings
18
Companies
1
Bought on market
None
Sold on market
$1.46M

Companies where Patrick Lamy is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Akero Therapeutics, Inc. logo
AKRO
Akero Therapeutics, Inc.
Senior VP, Commercial Strategysince January 20230$1.46MDec 9, 2025

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Patrick Lamy with

Other insiders at the same companies

Questions about Patrick Lamy

What is Patrick Lamy's role at Akero Therapeutics, Inc.?
Patrick Lamy reports to the SEC as senior VP and commercial Strategy at Akero Therapeutics, Inc. (AKRO), according to the latest filing on December 9, 2025.
Has Patrick Lamy bought or sold stock recently?
The most recent open-market sale was on July 1, 2025: sold 2,000 shares of Akero Therapeutics, Inc. (AKRO) for $106K at an average of $52.88.
How do I get alerts when Patrick Lamy files?
Follow Patrick Lamy on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Patrick Lamy (SEC CIK 0001961273). Totals count each trade once, skipping amendments whose original is on file, from Jan 12, 2023 on. View on SEC EDGAR